*Please note that Expert Review of Vaccines converted to a full Open Access journal from Volume 22 (2023). Previous volumes will continue to provide access through a Pay to Read model.
Expert Review of Vaccines (e-ISSN 1744-8395) is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed research in the development, application, and clinical effectiveness of new vaccines.
The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
The journal features cutting edge reviews and original articles on vaccines, the immune response, and the powerful impact of immunization against infectious diseases. We also cover vaccine technologies and platforms, adjuvants, therapeutic vaccines and vaccination for the control of non-communicable diseases.
Alongside review articles, the journal welcomes clinically relevant and novel original research. Pharmacoeconomic studies are considered if there is clear clinical relevance. Please note that the journal does not publish case reports, case series or animal studies. Letters to the Editor should discuss articles previously published in the journal.
Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;
Article Highlights – an executive summary of the author’s most critical points.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
For any pre-submission enquiries, please contact the Commissioning Editor.
Please note, from 2023 the Print ISSN is not in active use as this journal is no longer published in print.
Editor in Chief
Andrew J Pollard, University of Oxford, UK
Editorial Advisory Panel
Sergio Abrignani, National Institute of Molecular Genetics, Italy
Jon Kim Andrus, Sabin Vaccine Institute, Washington DC, USA
Vasso Apostolopoulos, Victoria University, Melbourne
Philip M Arlen, Precision Biologics, Washington DC, USA
P Noel Barrett, Baxter BioScience, Austria
Igor Belyakov, University of Michigan, MI, USA
Warwick Britton, The University of Sydney, NSW, Australia
Alexander Bukreyev, University of Texas Medical Branch, TX, USA
Myron Christodoulides, University of Southampton, UK
John Clemens, UCLA Fielding School of Public Health, USA
Angus G Dalgleish, St George's Hospital Medical School, UK
Ronald W Ellis, FutuRx Ltd, Israel
Gregory Glenn, Novavax, MD, USA
Michael Good, Griffith University, Queensland, Australia
Stephen Gordon, The Malawi Liverpool Wellcome Clinical Research Programme, Blantyre, Malawi
Stephen Hoffman, Sanaria Inc., MD, USA
Gagandeep Kang, Wellcome Trust Research Laboratory, Christian Medical College, Vellore, India
Jerome H. Kim, International Vaccine Institute, Seoul, South Korea
Odile Launay, Paris Descartes University, Cochin Hospital, Paris, France
Camille Locht, Institut Pasteur de Lille, France
Alex Loukas, James Cook University, Australia
Shabir Madhi, National Institute for Communicable Diseases, Johannesburg, South Africa
Elizabeth Miller, London School of Hygiene and Tropical Medicine, UK
Umesh Parashar, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Jan Poolman, Johnson & Johnson, Leiden, Netherlands
Punnee Pitisuttithum, Mahidol University, Bangkok, Thailand
Stanley Plotkin,University of Pennsylvania, Pennsylvania, USA
Firdausi Qadri,ICDDR,B, Dhaka, Bangladesh
Rino Rappuoli, Novartis Vaccines, Italy
Steven G Reed, Infectious Disease Research Institute, WA, USA
Gus Rimmelzwaan, Erasmus Medical Centre, Rotterdam, The Netherlands
Larisa Rudenko, Institute of Experimental Medicine, Saint Petersburg, Russia
Manish Sadarangani, Vaccine Evaluation Center, BC Children's Hospital Research Institute, BC, Canada
Suryaprakash Sambhara, CDC Atlanta, GA, USA
Alessandro Sette, La Jolla Institute for Allergy and Immunology, CA, USA
Leonard A. Smith, US Army Medical Research Institute of Infectious Diseases, MD, USA
De-chu Christopher Tang, International Vaccine Institute, Seoul, Korea
Ralph A Tripp, The University of Georgia, GA, USA
Takafumi Tsuboi, Ehime University, Ehime, Japan
Jeffrey Ulmer, GSK Vaccines, MD, USA
David B Weiner, University of Pennsylvania School of Medicine, PA, USA
Annelies Wilder-Smith, Lee Kong Chian School of Medicine, Singapore
Feng-Cai Zhu, Jiangsu Provincial Center for Disease Control and Prevention, China
Patrick L.F. Zuber, World Health Organization, Geneva, Switzerland
Peter Hotez, Baylor College of Medicine and Texas Children’s Hospital, TX, USA
Social Media Editor
Irsida Mehmeti, Catholic University "Our Lady of Good Counsel", Tiranë, Albania
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![Gates Open Research is a platform for rapid author-led publication and open peer review of research funded by the Bill & Melinda Gates Foundation.]({"type":"image" , "src" : "/sda/112431/GATES-KB.jpg"})